Sanofi India Limited announced its unaudited financial results for the quarter ended March 31, 2026, following a Board of Directors meeting on April 28, 2026. The company reported revenue from operations of ₹7,321 million for Q1 2026, representing a 74.4% increase from ₹4,198 million in the previous quarter (Q4 2025) and a 42.2% increase compared to ₹5,149 million in the corresponding quarter of the previous year. Net profit for the quarter reached ₹1,363 million, a significant growth of 120.9% from ₹617 million in the preceding quarter and a 49.3% increase from ₹913 million in the same period last year. This robust performance was primarily driven by exceptional growth in the insulin portfolio and a surge in export sales.

Sanofi India Limited is a leading pharmaceutical company with a seven-decade presence in India, specializing in high-value therapeutic areas such as diabetes, cardiovascular diseases, and vaccines. The company operates a significant manufacturing facility in Goa and continues to expand its reach through strategic partnerships and digital transformation initiatives. In 2025, Sanofi India focused on sharpening its diabetes portfolio and optimizing go-to-market strategies to ensure sustainable growth. The company also recently expanded its Global Capacity Centre (GCC) in Hyderabad to house up to 4,500 employees, underscoring its commitment to innovation and operational excellence in the region.